Corticosteroids for Pain

What They Are

Corticosteroids (or synthetic glucocorticoids) are analogs of endogenous cortisol, the hormone produced by the adrenal cortex that regulates inflammation, metabolism, and the response to stress. When given as medication, they have anti-inflammatory and immunosuppressive potency that far exceeds that of NSAIDs — and, proportionally, carry a more significant risk profile in prolonged use. For this reason, their place in pain is as a short-term tool in specific inflammatory situations, not as chronic treatment.

The class is organized by relative potency and duration of action. Among the short-acting agents, hydrocortisone is the most representative — used mainly in hospital emergencies and adrenal replacement. The intermediate-acting agents — prednisone, prednisolone, methylprednisolone, and triamcinolone — are the most used for pain and inflammation in outpatient practice, given the balance between anti-inflammatory efficacy and relatively predictable adrenal suppression. The long-acting agents — dexamethasone and betamethasone — are very potent and produce more rapid adrenal suppression; they have a place in neurologic emergencies (tumor edema, spinal cord compression) and in local injections.

It is important to distinguish corticosteroids from NSAIDs: although both reduce inflammation, the mechanism is different (corticosteroids act upstream, suppressing the transcription of dozens of inflammatory mediators; NSAIDs inhibit only the cyclooxygenases). The anti-inflammatory potency of corticosteroids is significantly greater — which explains their utility in severe flares — but the risk profile is also greater in prolonged use (osteoporosis, drug-induced diabetes, adrenal suppression, infection, psychiatric effects). The presentations used in pain cover three main routes: oral (short courses of prednisone or dexamethasone), intramuscular depot (methylprednisolone and betamethasone), and injection — articular, periarticular, or epidural.

Mechanism of Action

Corticosteroids exert two types of action. The genomic action, responsible for most of the therapeutic effect, involves binding to the cytoplasmic glucocorticoid receptor (GR), translocation of the complex to the nucleus, and modulation of the transcription of hundreds of genes — with suppression of inflammatory transcription factors such as NF-κB and AP-1. The result is an important reduction in the production of IL-1, IL-6, TNF-α, prostaglandins, leukotrienes, and proteolytic enzymes. This mechanism operates over a window of hours to days — it is potent, but not immediate.

The non-genomic action, less well known but clinically relevant, involves rapid effects on cell membranes and ion channels — responsible for part of the relief observed within minutes when high doses are administered intravenously (as in rheumatologic pulse therapy or neurologic emergency). This rapid effect helps explain why a dose of IV dexamethasone can improve symptoms of tumor compression within hours, before the genomic effect maximizes.

An important conceptual point: corticosteroids are not direct analgesics in the sense of modulating nociceptive transmission specifically. Pain relief comes from suppression of the inflammatory process that sustains it — less perineural edema in acute radiculopathy, less synovial inflammation in arthritis flare, less compression from peritumoral edema in oncology. This explains both their efficacy in inflammatory pain and their futility in established chronic neuropathic pain, fibromyalgia, or myofascial pain — conditions in which the inflammatory component is no longer the driver of the symptom.

Evidence by Context

Evidence for corticosteroids in pain varies dramatically by clinical context — and it is important not to treat "corticosteroids in pain" as a homogeneous block. In some situations they are standard of care with robust evidence; in others, broad practice diverges from what the literature actually supports.

In acute radiculopathy, the meta-analysis by Pinto et al. (Ann Intern Med 2012) of controlled trials of systemic corticosteroid in radicular pain from disc herniation showed a modest but consistent effect in reducing pain and disability when used in a short course in the first weeks — with better response in patients with marked functional deficit and recent symptom onset. The magnitude of the effect is smaller than common clinical perception suggests, but reproducible.

For intra-articular injection in osteoarthritis, the Cochrane review by Jüni et al. (2015) in knee OA identified a moderate, short-term effect (1-4 weeks), with return to baseline levels in 12-26 weeks. The effect size is clinically significant during a flare, but does not alter the natural history of the disease. The OARSI 2019 and NICE 2022 guidelines position injection as an adjuvant option in symptomatic OA flare — not as routine treatment — always combined with the foundational management (supervised exercise, weight loss, optimized analgesia).

Epidural injections have more nuanced evidence. The guidelines by Manchikanti et al. (Pain Physician) recognize benefit in selected acute radiculopathy, but efficacy in chronic non-radicular low back pain is weak. The FDA Safety Communication of 2014 warned about the risk of serious neurologic events — paralysis, stroke, death — associated with epidural corticosteroid injections, particularly when performed via the transforaminal route in the cervical spine. The alert led to refinement of technique, preferential use of non-particulate corticosteroids in certain contexts, and contraindication of cervical transforaminal use with particulate corticosteroids.

In inflammatory arthritis (RA, SLE, polymyalgia rheumatica), short courses of corticosteroid have robust evidence as a bridge to the underlying DMARD. The general position is clear: in acute inflammatory pain with a well-established indication, corticosteroid has a real and acceptable effect; in chronic pain without an active inflammatory substrate, the risk-benefit ratio does not justify it.

Indications (Restricted)

Indications for corticosteroids in pain are specific. The general principle: use them where there is a clear inflammatory component, for the shortest time possible, and never as chronic treatment in non-oncologic pain. The decision to prescribe — systemic or injection — requires a firm diagnosis, ruling out infection and contraindications, and explicit planning of duration and reassessment.

How They Are Used — the Short-Course Rule

The central operational principle is the short-course rule: in pain, systemic corticosteroids are typically used for 5-14 days in an inflammatory flare. This duration takes advantage of the acute anti-inflammatory benefit while keeping cumulative risks (osteoporosis, adrenal suppression, drug-induced diabetes) at an acceptable level. Use beyond 3 weeks enters another risk category and requires monitoring and gradual tapering.

Route selection depends on the clinical picture. In an inflammatory arthritis flare or acute radiculopathy, oral prednisone in an escalating and tapering schedule is the standard; in a neurologic emergency or rheumatologic pulse therapy, IV methylprednisolone is the choice. In OA flare or refractory bursitis, intra-articular or periarticular injection with depot methylprednisolone, triamcinolone, or betamethasone concentrates the effect on the target tissue with lower systemic exposure — but requires sterile technique and respect for the limit on applications per year per joint.

Corticosteroids — by generic name

Generic oral corticosteroids (prednisone, prednisolone, dexamethasone) are widely available at low cost in most countries through public health systems and private insurance. Injectable forms (IV methylprednisolone, depot methylprednisolone, betamethasone, triamcinolone) cover hospital, outpatient, and injection use, with variable coverage. For articular injections, depot methylprednisolone and betamethasone preparations are common outpatient choices.

Generic prednisone and dexamethasone are widely available at low cost. Outpatient injection with depot methylprednisolone or betamethasone is frequent practice — coverage varies by insurer. Hospital IV formulation covers rheumatologic emergencies (pulse therapy in severe SLE, RA flare), plus oncologic and neurologic emergencies. Relative accessibility should not be mistaken for harmlessness: the same ease of access that makes corticosteroids useful in a flare makes inappropriate prolonged use a real practical problem — patients self-medicating with prednisone for months or years, accumulating adverse effects without structured medical review, are commonly seen.

Dosing, Interactions, and Special Populations

General rules of dose and duration. For oral prednisone in acute flare, the usual range is 0.5-1 mg/kg/day with a ceiling of 60-80 mg/day; typical duration of 5-10 days in acute radiculopathy, 14-21 days in rheumatologic flare (often in a tapering schedule). For articular injection, 40-80 mg of depot methylprednisolone or 6-7 mg of betamethasone per application; minimum interval of 3 months between applications in the same joint.

For conversion between molecules (approximate anti-inflammatory equivalence), the classic reference applies: 0.75 mg of dexamethasone = 5 mg of prednisone = 4 mg of methylprednisolone = 20 mg of hydrocortisone. This equivalence guides switching between routes and drugs, but does not replace clinical reasoning — mineralocorticoid potency, duration of action, and the impact on adrenal suppression vary between molecules, even at equivalent anti-inflammatory doses.

Tapering. For use > 3 weeks, reduce 5-10 mg per week down to 20 mg/day of prednisone (or equivalent); below that, smaller reductions (2.5-5 mg every 1-2 weeks). Monitor for adrenal insufficiency symptoms (fatigue, nausea, hypotension, myalgia) — which may appear even with slow tapering.

Older adults. Increased risk of cascading adverse effects — hyperglycemia with decompensation of preexisting diabetes, hypertension, delirium, osteoporosis, myopathy, infection. Use lower doses and shorter courses whenever possible. Monitor capillary glucose and blood pressure during the cycle; in cycles > 2 weeks, consider bone prophylaxis with calcium and vitamin D (bisphosphonate in high risk).

People with diabetes. Drug-induced hyperglycemia is expected, not a complication — adjust hypoglycemic therapy (transient increase in insulin or metformin dose, addition of basal insulin in some cases) during the cycle, with return to the baseline regimen after the end. In a patient with prior metabolic decompensation, weigh alternatives and monitor glucose frequently.

People with hypertension. Blood pressure elevation is expected with use > 2 weeks; monitor and adjust antihypertensives as needed. In decompensated heart failure, systemic use is relatively contraindicated — fluid retention can precipitate worsening.

Pregnant women. Prednisone and prednisolone are relatively safe as a short course (category C) — most is metabolized in the placenta and fetal exposure is low. Dexamethasone and betamethasone cross the placenta more freely (used intentionally for fetal lung maturation); for pain management in a pregnant patient, prednisone is preferred as a short course when needed. Individual decision with the obstetrician.

Lactating women. Prednisone is compatible with breastfeeding at low-moderate doses (< 20 mg/day); at high prolonged doses, feedings can be spaced 4 hours from the dose. Decision in conjunction with the pediatrician.

People with osteoporosis or advanced age with risk factor. For planned use > 3 months, consider prophylaxis with calcium + vitamin D; add bisphosphonate in high fracture risk. Baseline bone densitometry is prudent in chronic users.

Risks and Adverse Effects

The risks of corticosteroids are dose- and time-dependent: in well-indicated short cycles, most patients tolerate them well, with mild and reversible adverse effects (insomnia, mood changes, mild hyperglycemia). In prolonged use, the picture changes radically — and it is at this point that pressure to continue treatment must be critically reassessed against the accumulation of risks.

In a patient with unplanned chronic use — discovered in the history, for example prednisone 5-10 mg/day for months or years on the patient's own initiative or by prescription without reassessment — management involves review of the original indication, slow supervised tapering, evaluation of acquired metabolic and bone comorbidities, and active search for a more appropriate therapeutic alternative. Stopping abruptly in this context is dangerous; maintaining without reassessment is worse.

One practical caveat: patients on chronic corticosteroids should have this recorded for stress dosing in procedures (surgery, severe infection) — the suppressed adrenal reserve does not respond to increased demand, and supplementation with IV hydrocortisone may be necessary. A medical alert card is recommended practice in prolonged use.

Limitations and What Is Still Not Known

Even after decades of clinical use, important gaps remain — and popular notions about corticosteroid injection need to be reconstructed in light of what the evidence actually supports.

Evidence Gaps

Epidural injection in chronic non-radicular pain. The evidence is weak, but the procedure is widely performed outside contexts with robust support. The literature indicates benefit in selected acute radiculopathy; in chronic mechanical low back pain without a clear radicular component, the gain is small and often does not justify the risk (especially after the FDA 2014 alert).

Ideal dose, interval, and drug for articular injection are not fully agreed upon. Practice varies between services — methylprednisolone 40 mg vs. 80 mg, betamethasone vs. triamcinolone, interval of 3 vs. 4 months. Guidelines converge on the principle (limited use, adjuvant to baseline treatment), but diverge in technical details.

Established chronic neuropathic pain. Negative or insufficient evidence — corticosteroids have no place in chronic management of diabetic neuropathy, established postherpetic neuralgia, or central neuropathic pain. In these conditions, the substrate is somatosensory pathway sensitization and dysfunction, not active tissue inflammation.

Deflazacort as a "bone-sparing" alternative. The molecule is marketed as having lower bone impact than prednisone, but non-inferiority data for pain (versus superior bone safety) are limited. In practice, it may be considered in patients with bone risk factors and planned prolonged use — but without definitive evidence.

Repeated intermittent short cycles. The safety of, say, 2-3 short courses of prednisone per year (in a recurrent condition) has not been systematically studied. Clinical practice accepts this repetition provided each cycle is well indicated and no cumulative signs appear, but the topic deserves formal investigation.

Relationship with Medical Acupuncture

Medical acupuncture occupies a useful complementary space in the conditions where corticosteroids carry the most cumulative risk — exactly the mild-to-moderate chronic pain and recurrent conditions. In chronic headache, myofascial pain, mild articular pain, and some controlled chronic inflammatory pain settings, integration with acupuncture can reduce the need for repeated cycles of oral corticosteroid throughout the year. There is no pharmacologic interaction — the combination is safe.

In severe acute flares (disabling acute radiculopathy, active inflammatory arthritis), the corticosteroid in a short course is often the most effective instrument to control the inflammatory peak — acupuncture is adjuvant, not a substitute, in these acute scenarios. The rational place is to think of an integrated multimodal plan (discussed in acupuncture in multimodal treatment), in which each tool is used where it has the greatest relative benefit.

When to Seek Medical Help

Corticosteroids require medical evaluation both to start with the correct indication and to monitor use and taper safely. Some contexts demand more urgent or emergency evaluation.